Kairos Pharma Ltd., a clinical-stage biopharmaceutical company, has received a Department of Defense grant to support its ongoing lung cancer biomarker research. The company is currently advancing two clinical trials for its lead candidate ENV105, targeting prostate and EGFR-dependent non-small cell lung cancers.
The research focuses on ENV105, an antibody designed to target CD105, a protein identified as a key driver of drug resistance in cancer treatments. By addressing the mechanism that leads to treatment resistance and disease relapse, Kairos aims to restore the effectiveness of standard cancer therapies across multiple cancer types.
The company is expecting to release safety and interim efficacy results for its clinical trials in the second quarter of 2025. Simultaneously, Kairos is developing KROS101, an immune response modulator, with recent data presented at prominent oncology conferences.
The non-dilutive government grant represents a significant milestone for Kairos, providing financial support for its innovative research. The company's strong financial position is further bolstered by analyst coverage from firms like EF Hutton and HC Wainwright, and an intellectual property portfolio extending into the 2030s.
This research could potentially transform cancer treatment by addressing a critical challenge in oncology: drug resistance. By targeting CD105, Kairos Pharma is working to develop therapies that could improve patient outcomes and extend treatment effectiveness for patients with prostate and lung cancers.
